TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in color after the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gene expression pattern associated with recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in the Montgomery-Asberg Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Extracellular Volume (ECV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration of graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hemagglutinin inhibition titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection rate of syndesmotic screw contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in mean ambulatory arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cost Differences
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rumination Response Scale -10 items (RRS10)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perseverative Thinking Questionnaire (PTQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Anxiety Sensitivity Index 16 (ASI16)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in gas trapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SAEs - Safety of treatment and the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants to Experience a Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Neutrophil Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neuropathic Element of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI calculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Dose-Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in PTSD Checklist (PCL-M) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Subjects Stricture Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Major Device or Procedure Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of aneurysm recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinical Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAT positive and negative predictive values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of airflow obstruction compatible with COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in beta symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 16 weeks progression-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of InflammaDry Detector
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale for Pain Intensity (VAS) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of adenomas and advanced neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MAO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation dose of the operator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Disability Arm Shoulder Hand Questionnaire (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of familial hypercholesterolemia or pre-type-1-diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with abdominal reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: Institutional delivery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Minutes spent engaging in physical activity during each phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average heart rate for each phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine Response to Serum Bactericidal Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PVC Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac Ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma expression of miR-320a
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection rate of subtle structural epileptogenic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in mobility function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in performance in activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in occupational performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Plasma concentrations of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in children's heart rate (HR) as a somatic response to anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change from baseline in children's systolic blood pressure (SBP) as a somatic response to anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: children's preoperative anxiety at holding area
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Reporting Treatment-Emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Level of eosinophils in nasal lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic contribution of biopsy procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Functional Capacity from Baseline
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Physical Frailty from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fatigue from Baseline
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change from Baseline in neck/scapular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Pharmacokinetics (PK) parameters of LEE011
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of glucose disappearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intra- and postoperative volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Ratio of Dose and Defined Daily Dose (DDD) for Anti-Epileptic Drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Study Discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in haemodynamic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip Strength of Affected Hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strickland modified Total Active Motion (TAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal Cardiac Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anti müllerian hormone (AMH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants With Untoward Events
Endpoint domain: Adverse events/effects
Primary endpoint: Time from first medical contact to final patient disposition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pulmonary deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Size of Polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: FFR Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart function determined by ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety as measured by serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Incidence of SARS-CoV-2 Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Incidence of Grade II-IV Acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who score greater than 60 on the Barthel Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of participants who score greater than 26 on the Montreal Cognitive Assessment (MoCA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants who score 1 or less on the Modified Rankin Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of participants who have experienced adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who score greater than 75 on the EuroQOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in adipose tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline of Bacterial Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from Baseline of Oral Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraktionele collagen protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Proximal Contact (modified USPHS criteria)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Liebowitz Social Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eastern Cooperative Oncology Group (ECOG) Performance Status at Each Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate Cancer Detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Aggressiveness Monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diabetic retinopathy grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Overnight Change on Finger Tapping Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Spindle Density During Stage 2 Sleep as Measured by Polysomnography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration at steady state (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum observed plasma concentration at steady state (Cmin,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve over a dosing interval (AUCτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical signs and symptoms of pulp reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic signs of pulp reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of non-behavioral phenotypical traits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in score on Generalized Anxiety Stigma Scale (GASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in score on Depression Stigma Scale (DSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in score on Attitudes Towards Seeking Professional Help Scale (ATSPH)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Assessment of musculoskeletal systems in motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Distribution of acetate metabolism during exercise skeletal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in general health outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of RRT-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Stop Signal Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive effects
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: proportion cured at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lifestyle program adherence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Patients' experiences of anger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Health care professionals' experiences of anger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Health care professionals' experiences of attitudes towards and treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cure of the diseases
Endpoint domain: Mortality/survival
Primary endpoint: Time to Achieve a > 30% Decrease From Baseline in Intact Parathyroid Hormone (iPTH) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants With Calcium x Phosphorus Product (CxP) Values > 65 mg˄2/dL˄2 or 5.24 mmol˄2/L˄2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Eradication rate for H. pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With TEAEs Leading to Study Drug Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Fatal TEAE
Endpoint domain: Adverse events/effects
Primary endpoint: number of thalassemic patients with impaired glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of gemigliptin, LC 15-0636 and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tlast of gemigliptin, LC 15-0636 and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ of gemigliptin, LC 15-0636 and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Cigarettes Smoked Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal leg press strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work economy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of weekly acupuncture sessions completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Data completeness in survey questionnaires
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participants' perceptions of feasibility of the study
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cerebral blood flow correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetics of moxifloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: acute kidney injury incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Major Adverse Cardiac Events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: HAI response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Health-Promotion Lifestyle
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Cases Successfully Treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kaplan-Meier survivorship at the five-year period
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Plasma Concentration (Tmax) of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-infinity) of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in isometric hip and trunk muscles strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in 8UG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10MW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average nocturnal blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage dipping of nocturnal blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nadir of nocturnal blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in mood elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in interest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of employees eligible for lung cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma drug concentration (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Aqueous Humor Concentration of Moxifloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity at 6 weeks post infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Persistence and frequency of circulating EBV CTL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Radiographic Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak walking time (PWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to normal creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Stone free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Operative and early post operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: post-laparoscopic cholecystectomy pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration of AngiotensinⅡ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time of presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cessation of Status epilepticus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the number of intrusive memories of traumatic event
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Decrease in ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Symptom Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Diaphragm Excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sexual violence in the past 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: risk-adjusted kidney yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: E-selectin, VCAM-1, P-selectin, fibrinogen, PAI-1, MCP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes